Skip to main content
Top
Published in: Rheumatology International 6/2017

01-06-2017 | Health Services Research

Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?

Authors: Bee Eng Tan, Ai Lee Lim, Sow Lai Kan, Chong Hong Lim, Ying Fun Ng, Serene Li Ching Tng, Nur Syakirah Hassin, Losshenee Chandran, Norshahida Abdul Hamid, Yvonne Yin Leng Lee

Published in: Rheumatology International | Issue 6/2017

Login to get access

Abstract

To evaluate the achievement of treat-to-target (T2T) strategy in rheumatoid arthritis (RA) and identify factors associated with failed treatment target in a public rheumatology center. A cross-sectional study was conducted from June 2015 to February 2016. RA patients with disease duration greater than 2 years and under T2T for over a year were invited to the study. Demographic, clinical data, disease activity score of 28 joints (DAS28), and clinical disease activity index (CDAI) were collected in a single routine clinic visit. Treatment target was defined as DAS28 <3.2 or CDAI ≤10. Retrospective chart review was performed to determine reasons of failed treatment target. A total of 371 patients were recruited and 87.1% were female. Mean age and duration of RA were 53.5 years (SD 10.3) and 9.1 years (SD 6.6), respectively. Ethnic distribution was 49% Chinese, 27% Malay, and 24% Indian. T2T was achieved in 81.7% of the cohort. Non-Chinese ethnicity, positive rheumatoid factor, and treatment with three disease modifying anti-rheumatic drugs (DMARDs) were associated with failed treatment target. After controlling for covariates, Malay ethnicity (OR 2.96; 95% CI 1.47–5.96) and treatment with three DMARDs (OR 2.14; 95% CI 1.06–4.35) were associated with failed treatment target. There was no association between age, gender, duration of RA, BMI, smoking status, anti-citrulinated cyclic peptide, and achievement of T2T. The most common reasons of failed treatment target were inability to escalate DMARDs due to side effects (18.8%), lack of biologics fund (15.6%), and persistent disease despite optimum treatment (14.1%). T2T was successfully implemented. Malay patients need aggressive treatment adaptation to achieve optimal outcome.
Literature
1.
go back to reference Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631–637. doi:10.1136/ard.2009.123919 CrossRefPubMedPubMedCentral Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien TK, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631–637. doi:10.​1136/​ard.​2009.​123919 CrossRefPubMedPubMedCentral
2.
go back to reference Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3–15. doi:10.1136/annrheumdis-2015-207524 CrossRefPubMed Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compán MV, Oliver S, Schoels M, Scholte-Voshaar M, Stamm T, Stoffer M, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma H, Burkhardt H, Cardiel M, Combe B, Durez P, Fonseca JE, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Haraoui B, Kouloumas M, Landewe R, Martin-Mola E, Nash P, Ostergaard M, Östör A, Richards P, Sokka-Isler T, Thorne C, Tzioufas AG, van Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3–15. doi:10.​1136/​annrheumdis-2015-207524 CrossRefPubMed
3.
go back to reference Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O’Dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64(5):640–647. doi:10.1002/acr.21649 CrossRef Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O’Dell JR, Kazi S (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64(5):640–647. doi:10.​1002/​acr.​21649 CrossRef
4.
go back to reference Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43(10):1252–1255. doi:10.1093/rheumatology/keh297 CrossRef Fransen J, Creemers MC, Van Riel PL (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43(10):1252–1255. doi:10.​1093/​rheumatology/​keh297 CrossRef
5.
go back to reference Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796–R806. doi:10.1186/ar1740 CrossRefPubMedPubMedCentral Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7(4):R796–R806. doi:10.​1186/​ar1740 CrossRefPubMedPubMedCentral
6.
go back to reference Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Kerstens PJSM, Nielen MMJ, Vos K, van Schaardenburg D, Speyer I, Seys P EH, Breedveld FC, Allaart CF, Dijkmans BAC (2010) DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 69(01):65–69. doi:10.1136/ard.2008.097683 CrossRefPubMed Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Kerstens PJSM, Nielen MMJ, Vos K, van Schaardenburg D, Speyer I, Seys P EH, Breedveld FC, Allaart CF, Dijkmans BAC (2010) DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 69(01):65–69. doi:10.​1136/​ard.​2008.​097683 CrossRefPubMed
7.
go back to reference Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263–269. doi:10.1016/s0140-6736(04)16676-2 CrossRefPubMed Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263–269. doi:10.​1016/​s0140-6736(04)16676-2 CrossRefPubMed
8.
go back to reference Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS, on behalf of the Optimization of Adalimumab Trial I (2013) Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a Real-World Cluster-Randomized Adalimumab Trial. Arthritis Care Res 65(9):1401–1409. doi:10.1002/acr.22010 CrossRef Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS, on behalf of the Optimization of Adalimumab Trial I (2013) Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a Real-World Cluster-Randomized Adalimumab Trial. Arthritis Care Res 65(9):1401–1409. doi:10.​1002/​acr.​22010 CrossRef
9.
go back to reference Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Broeder AAD, Riel Pv, Fransen J, van de Laar MA (2012) A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 71(6):845–850. doi:10.1136/annrheumdis-2011-200274 CrossRefPubMed Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Broeder AAD, Riel Pv, Fransen J, van de Laar MA (2012) A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 71(6):845–850. doi:10.​1136/​annrheumdis-2011-200274 CrossRefPubMed
10.
go back to reference Schoels M, Knevel R, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas DT, Burmester G, Combe B, Cutolo M, Dougados M, Emery P, van der Heijde D, Huizinga TWJ, Kalden J, Keystone EC, Kvien TK, Martin-Mola E, Montecucco C, de Wit M, Smolen JS (2010) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 69(4):638–643. doi:10.1136/ard.2009.123976 CrossRefPubMedPubMedCentral Schoels M, Knevel R, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas DT, Burmester G, Combe B, Cutolo M, Dougados M, Emery P, van der Heijde D, Huizinga TWJ, Kalden J, Keystone EC, Kvien TK, Martin-Mola E, Montecucco C, de Wit M, Smolen JS (2010) Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 69(4):638–643. doi:10.​1136/​ard.​2009.​123976 CrossRefPubMedPubMedCentral
12.
go back to reference Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66(11):1443–1449. doi:10.1136/ard.2007.071092 CrossRefPubMedPubMedCentral Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66(11):1443–1449. doi:10.​1136/​ard.​2007.​071092 CrossRefPubMedPubMedCentral
13.
go back to reference Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JWJ, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JMW, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PLCM, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204573 Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JWJ, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JMW, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PLCM, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2013-204573
14.
go back to reference Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O’Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(1):1–25. doi:10.1002/acr.22783 CrossRef Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O’Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(1):1–25. doi:10.​1002/​acr.​22783 CrossRef
16.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed
17.
go back to reference Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580–1588. doi:10.1136/ard.2010.138461 CrossRefPubMed Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580–1588. doi:10.​1136/​ard.​2010.​138461 CrossRefPubMed
22.
go back to reference Koh ET, Tan JWL, Thong BY-H, Teh CL, Lian TY, Law WG, Earnest A, Kong KO, Lau TC, Cheng YK, Howe HS, Yong WH, Chia FL-A, Chng HH, Leong KP (2013) Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore. Rheumatol Int 33(7):1693–1703. doi:10.1007/s00296-012-2602-2 CrossRefPubMed Koh ET, Tan JWL, Thong BY-H, Teh CL, Lian TY, Law WG, Earnest A, Kong KO, Lau TC, Cheng YK, Howe HS, Yong WH, Chia FL-A, Chng HH, Leong KP (2013) Major trends in the manifestations and treatment of rheumatoid arthritis in a multiethnic cohort in Singapore. Rheumatol Int 33(7):1693–1703. doi:10.​1007/​s00296-012-2602-2 CrossRefPubMed
23.
go back to reference Hetland ML, Jensen DV, Krogh NS (2014) Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. Clin Exp Rheumatol 32 (5 Suppl 85):S-141–S-146 Hetland ML, Jensen DV, Krogh NS (2014) Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry. Clin Exp Rheumatol 32 (5 Suppl 85):S-141–S-146
24.
go back to reference Van Hulst LT, Kievit W, Van Bommel R, Van Riel PL, Fraenkel L (2011) Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken) 63(10):1407–1414. doi:10.1002/acr.20551 CrossRef Van Hulst LT, Kievit W, Van Bommel R, Van Riel PL, Fraenkel L (2011) Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment. Arthritis Care Res (Hoboken) 63(10):1407–1414. doi:10.​1002/​acr.​20551 CrossRef
26.
go back to reference Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Margaretten M, Chernitskiy V, Graf J, Imboden J, Yelin E (2011) Racial and Ethnic Disparities in Disease Activity and Function among Persons with Rheumatoid Arthritis from University-Affiliated Clinics. Arthritis Care Res 63(9):1238–1246 Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Margaretten M, Chernitskiy V, Graf J, Imboden J, Yelin E (2011) Racial and Ethnic Disparities in Disease Activity and Function among Persons with Rheumatoid Arthritis from University-Affiliated Clinics. Arthritis Care Res 63(9):1238–1246
27.
go back to reference Bruce B, Fries JF, Murtagh KN (2007) Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol 34(7):1475–1479PubMed Bruce B, Fries JF, Murtagh KN (2007) Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol 34(7):1475–1479PubMed
29.
go back to reference Yazici Y, Kautiainen H, Sokka T (2007) Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol 34(2):311–315PubMed Yazici Y, Kautiainen H, Sokka T (2007) Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol 34(2):311–315PubMed
31.
go back to reference Kong KF, Yeap SS, Chow SK, Phipps ME (2002) HLA-DRB1 genes and susceptibility to rheumatoid arthritis in three ethnic groups from Malaysia. Autoimmunity 35(4):235–239CrossRefPubMed Kong KF, Yeap SS, Chow SK, Phipps ME (2002) HLA-DRB1 genes and susceptibility to rheumatoid arthritis in three ethnic groups from Malaysia. Autoimmunity 35(4):235–239CrossRefPubMed
32.
go back to reference Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ (Clin Res) 353:i1777. doi:10.1136/bmj.i1777 Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe D, Bombardier C (2016) Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis. BMJ (Clin Res) 353:i1777. doi:10.​1136/​bmj.​i1777
35.
go back to reference Too CL, Yahya A, Murad S, Dhaliwal JS, Larsson PT, Muhamad NA, Abdullah NA, Mustafa AN, Klareskog L, Alfredsson L, Padyukov L, Bengtsson C (2012) Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther 14(2):R89. doi:10.1186/ar3813 CrossRefPubMedPubMedCentral Too CL, Yahya A, Murad S, Dhaliwal JS, Larsson PT, Muhamad NA, Abdullah NA, Mustafa AN, Klareskog L, Alfredsson L, Padyukov L, Bengtsson C (2012) Smoking interacts with HLA-DRB1 shared epitope in the development of anti-citrullinated protein antibody-positive rheumatoid arthritis: results from the Malaysian Epidemiological Investigation of Rheumatoid Arthritis (MyEIRA). Arthritis Res Ther 14(2):R89. doi:10.​1186/​ar3813 CrossRefPubMedPubMedCentral
36.
go back to reference Fisher MC, Hochberg MC, El-Taha M, Kremer JM, Peng C, Greenberg JD (2012) Smoking, smoking cessation, and disease activity in a large cohort of patients with rheumatoid arthritis. J Rheumatol 39(5):904–909. doi:10.3899/jrheum.110852 CrossRefPubMed Fisher MC, Hochberg MC, El-Taha M, Kremer JM, Peng C, Greenberg JD (2012) Smoking, smoking cessation, and disease activity in a large cohort of patients with rheumatoid arthritis. J Rheumatol 39(5):904–909. doi:10.​3899/​jrheum.​110852 CrossRefPubMed
37.
go back to reference Lu B, Rho YH, Cui J, Iannaccone CK, Frits ML, Karlson EW, Shadick NA (2014) Associations of smoking and alcohol consumption with disease activity and functional status in rheumatoid arthritis. J Rheumatol 41(1):24–30. doi:10.3899/jrheum.130074 CrossRefPubMed Lu B, Rho YH, Cui J, Iannaccone CK, Frits ML, Karlson EW, Shadick NA (2014) Associations of smoking and alcohol consumption with disease activity and functional status in rheumatoid arthritis. J Rheumatol 41(1):24–30. doi:10.​3899/​jrheum.​130074 CrossRefPubMed
38.
go back to reference Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C (2016) The impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). doi:10.1002/acr.22932 Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C (2016) The impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). doi:10.​1002/​acr.​22932
39.
go back to reference Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 62(8):1128–1143. doi:10.1002/acr.20188 CrossRef Katchamart W, Johnson S, Lin HJ, Phumethum V, Salliot C, Bombardier C (2010) Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 62(8):1128–1143. doi:10.​1002/​acr.​20188 CrossRef
Metadata
Title
Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?
Authors
Bee Eng Tan
Ai Lee Lim
Sow Lai Kan
Chong Hong Lim
Ying Fun Ng
Serene Li Ching Tng
Nur Syakirah Hassin
Losshenee Chandran
Norshahida Abdul Hamid
Yvonne Yin Leng Lee
Publication date
01-06-2017
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 6/2017
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-017-3705-6

Other articles of this Issue 6/2017

Rheumatology International 6/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.